Two separate studies have been reported comparing Corynebacterium parvum and bacille Calmette-Guérin (BCG) as adjuvant immunotherapy for stage II melanoma patients (The Milton S. Hershey Medical Center, 48 patients; Southeastern Cancer Study Group [SECSG], 162 patients). As the criteria for patient selection and drugs used were similar, we have pooled the data to analyze the effects of these two treatments. Both studies used BCG (Tice, Chicago, IL) 3 x 10(8) live organisms per treatment by Tine technique and C parvum (Burroughs-Wellcome, Triangle Park, NC) subcutaneous at a dose of 4 mg/m2 (SECSG) or 5 micrograms/m2 (Hershey) per treatment. The only difference in these studies was the frequency of immunization, with patients in Hershey receiving 22 doses and the SECSG patients receiving 55 doses during the 2-year period of treatment. Kaplan-Meier life-table analysis for the 210 patients shows a prolonged disease-free interval for patients treated with C parvum (P = .02, two-sided Mantel procedure). In similar fashion, patients treated with C parvum had an improved survival rate (from all causes) when compared with BCG-treated patients (P = .012). An analysis of the results for the 170 patients for which the number of positive nodes was available was performed using Cox's model, with nodes as a stratification variable and with covariates of place, treatment, age, and sex. In this analysis, an observed benefit for C parvum on the disease-free interval had a P value of .37 while the benefit of C parvum on the survival times (from all causes) had a P value of .04. When the same analysis was performed using only patients aged younger than 60 years, the observed benefit of C parvum on disease-free interval had a P value of .08 and the benefit of C parvum on survival times (from all causes) had a P value of .008.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.1991.9.7.1151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
J Infect Dis
November 2023
State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory of Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.
Background: Cryptosporidiosis is a significant diarrheal disease in humans and animals. Immunodeficient mice are the primary small animal models, but their high costs and specialized breeding/housing requirements limit in vivo drug testing. Numerous anticryptosporidial lead compounds identified in vitro remain untested in vivo.
View Article and Find Full Text PDFPhotoswitchable Inhibitors to Optically Control Specific Kinase Activity.
ACS Chem Biol
June 2023
Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.
Article Synopsis
- Researchers developed small molecules that can selectively inhibit protein kinases, specifically targeting calcium-dependent protein kinase 1 (CDPK1), using a new class of photoswitchable azopyrazoles.
- These azopyrazoles enable dynamic control of CDPK1 activity by applying light of different wavelengths, allowing for fine-tuned timing in biological experiments.
- The study reveals that the effectiveness of these inhibitors is influenced by the size of the "gatekeeper" residue in CDPK1, and shows potential use against certain infections in cell cultures, paving the way for future applications in targeted kinase research.
Structural Analyses of a Dominant Cryptosporidium parvum Epitope Presented by H-2K Offer New Options To Combat Cryptosporidiosis.
mBio
February 2023
College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, People's Republic of China.
Cryptosporidium parvum has gained much attention as a major cause of diarrhea in the world, particularly in those with compromised immune systems. The data currently available on how the immune system recognizes C. parvum are growing rapidly, but we lack data on the interactions among host major histocompatibility complex (MHC) diversity and parasitic T-cell epitopes.
View Article and Find Full Text PDFIntestinal immune responses to commensal and pathogenic protozoa.
Front Immunol
October 2022
Molecular Parasitology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
The physical barrier of the intestine and associated mucosal immunity maintains a delicate homeostatic balance between the host and the external environment by regulating immune responses to commensals, as well as functioning as the first line of defense against pathogenic microorganisms. Understanding the orchestration and characteristics of the intestinal mucosal immune response during commensal or pathological conditions may provide novel insights into the mechanisms underlying microbe-induced immunological tolerance, protection, and/or pathogenesis. Over the last decade, our knowledge about the interface between the host intestinal mucosa and the gut microbiome has been dominated by studies focused on bacterial communities, helminth parasites, and intestinal viruses.
View Article and Find Full Text PDF: A Novel Species Causing Stem Blight and Dieback of Blueberries in China.
Plant Dis
September 2022
Institute of Microbiology, School of Ecology and Nature Conservation, Beijing Forestry University, Beijing 100083, People's Republic of China.
Blueberries ( spp.) have been considered to be a superfood because of their health benefits. Stem blight or dieback of blueberry has been frequently observed in commercial plantations, with incidences between 15 and 30% being observed in China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!